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Stress Pathways and Heart Failure Minireview
thinning of the walls of the ventricular chamber (FigureKenneth R. Chien, M.D., Ph.D.
UCSDÐSalk Program in Molecular Medicine 1). Familial hypertrophic cardiomyopathy, which at first
UCSD School of Medicine is not accompanied by chamber dilation, occurs due to
La Jolla, California 92093 mutations affecting proteins in the sarcomere, which
comprises the contractile machinery of heart muscle
(Seidman and Seidman, 1999), while familial dilated car-
The study of complex heart diseases has always been diomyopathy has now been linked to mutations in cy-
a vexing task, akin to solving a 1000-part jigsaw puzzle toskeletal genes (for a list, see Chen and Chien, 1999).
with few obvious connecting pieces. Acquired cardio- In addition, mice harboring muscle-specific mutations in
vascular diseases, such as atherogenesis and heart fail- extra-sarcomeric cytoskeletal proteins display a dilated
ure, arise via the interaction of environmental factors cardiomyopathy phenotype, consistent with a direct role
and genetic susceptibility to produce complicated le- of the cytoskeleton in intrinsic signals for dilated cardio-
sions that cannot be explained by a single gene or path- myopathy. Accordingly, it is now critical to show
way. Distinguishing primary from secondary events, whether these cytoskeletal proteins have a nonspecific
proving causality, and finding the intersecting pieces structural role or a specific signaling role in chamber
has proven a significant challenge. Nevertheless, as evi- dilation.
denced by the pioneering work on the LDL receptor Cytoskeletal Pathways and Dilated Cardiomyopathy
pathway in atherogenesis, genetic-based analysis of rel- The first genetic link between the cytoskeleton and car-
atively rare diseases that exhibit the clinical cardiovas- diomyopathy was provided by the discovery that muta-
cular phenotype of interest can yield mechanistic insight tions in dystrophin or its associated proteins can cause
into complex heart diseases (Brown and Goldstein, familial forms of dilated cardiomyopathy and skeletal
1997). Often, this requires not only identifying the dis- myopathies (Figure 2). Duchenne and Becker muscular
ease gene, but eventually connecting the gene to molec- dystrophy, two of the most common genetic neuromus-
ular pathways that initiate, promote, suppress, and po- cular diseases, are caused by a variety of mutations in
tentially reverse surrogate endpoints of the disease the dystrophin gene. The sarcoglycan proteins are a
phenotype. Ironically, the dramatic improvement in sur- subcomplex of transmembrane proteins within the
vival from acute coronary disease has led to an increase dystrophin±glycoprotein complex (DGC) (reviewed by
in heart failure of epidemic proportions, which now is Hemler, 1999). Mutation of sarcoglycan genes results in
the leading cause of combined morbidity and mortality limb girdle muscular dystrophies (LGMDs), and these
in the US and other developed nations. Unfortunately,
our understanding of the molecular pathways leading
to heart failure is primitive, and the ªcholesterol,º i.e., key
risk factor, that drives the underlying disease process is
unknown. However, a flurry of recent papers describing
rare monogenic forms of human dilated cardiomyopathy
and gene-targeted mouse models of muscle-specific
mutations have allowed the identification of genetic
pathways that can lead to dilated cardiomyopathy, a
major form of human heart failure characterized by a
progressive, uniform dysfunction of the entire myocar-
dium. Since dilated cardiomyopathy can occur indepen-
dently of coronary artery disease, and often has a ge-
netic component, analysis of this subset of heart failure
provides an opportunity to uncover intrinsic muscle-
specific pathways for heart failure. This minireview will
highlight these pieces of the dilated cardiomyopathy
puzzle that may serve as a paradigm for acquired forms
of heart failure.
Distinct Biomechanical Stress Pathways
for Dilated Cardiomyopathy
Biomechanical stress resulting from hypoxia, hyperten-
Figure 1. Distinct Gene Mutations Can Give Rise to Either Hypertro-sion, and other forms of myocardial injury is the first
phic or Dilated Forms of Cardiomyopathycornerstone of any proposed model of dilated cardiomy-
Mutations within sarcomeric genes give rise to a hypertrophic car-opathy. The loss of functional myocardium creates addi-
diac phenotype, whereas mutations within components of the extra-tional biomechanical stress on the remaining viable
sarcomeric cytoskeleton give rise to dilated cardiac phenotypes.heart muscle, thereby triggering signals for a compensa-
Unknown genetic modifiers also can lead to the conversion of hyper-
tory increase in cardiac muscle mass, known as hyper- trophic to dilated forms of cardiomyopathy. (For a list of mutations,
trophy (reviewed by Chien et al., 1999). A transition can see Seidman and Seidman, 1999 and Chen and Chien, 1999.) Red,
occur whereby an irreversible decompensation in car- cardiac muscle; beige, valvular structures. Ao, aorta; LA, left atrial
chamber; LV, left ventricular chamber.diac function occurs during the dilation of the heart and
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is restricted to skeletal and cardiac muscle, whereas b,
d, and e subunits are also expressed in other tissues.
Mice lacking the a or d subunit have no detectable sar-
coglycan complex in both skeletal muscle and heart.
However, the two mouse models differ in their pheno-
typic presentation. Both types of mice develop skeletal
muscle dystrophy, yet only the d knockout mice exhibit
cardiomyopathy. In keeping with the expression profile
of each subunit, the d, but not the a, knockout mice
exhibit a substantial loss of the sarcoglycan complex in
vascular smooth muscle. This loss is associated with
vascular malfunction and irregularities of coronary artery
vasculature. The demonstration that vascular defects
may be a pivotal factor in the development of some
cardiomyopathies opens the door to novel therapeutic
targets.
Microvascular dysfunction associated with focal myo-
cardial necrosis had been described previously in a
hamster model, BI014.6, of hypertrophic cardiomyopa-
thy that has subsequently been shown to be the result
of a 59 deletion of the d-sarcoglycan gene (see Coral-
Vazquez et al., 1999, and references therein). It will be
of interest to reexamine this hamster model in light of the
Campbell group's findings. Interestingly a strain derived
from BIO14.6, TO-2, carries the same deletion but exhib-
its dilated, rather than hypertrophic cardiomyopathy.
This clearly demonstrates that another genetic modifier
gene(s) is involved in the manifestations of cardiomy-Figure 2. Critical Protein Components of the Cytoskeletal Network
and Sarcoplasmic Reticulum in Heart Muscle opathy.
Despite this exciting new finding, it is clear that notThe upper figure is a three-dimensional representation of two myofi-
brils and associated sarcolemmal, T-tubular, and sarcoplasmic re- all cardiomyopathies associated with sarcoglycan defi-
ticular membranes within a cardiomyocyte. The panel on the bottom ciency can be attributed to vascular smooth muscle
left depicts the interconnecting pathway between the extracellular involvement. Mice lacking the g subunit which, like a, is
matrix (laminin-2) and the nucleus (lamin A/C) via the dystrophin-
selectively expressed in striated muscle, also evidence aglycoprotein complex and proteins within the Z line of the sarco-
reduction in the sarcoglycan complex in both skeletalmere. Mice that are null for muscle LIM protein (MLP) develop dilated
and cardiac muscle. However, in contrast to the a knock-cardiomyopathy. Asterisks denote proteins for which gene muta-
tions have been shown to cause dilated cardiomyopathy. The panel out, g knockout mice display both muscular dystrophy
on the bottom right depicts SR calcium pathways within cardiomyo- and cardiomyopathy. This discrepancy remains to be
cytes. During systolic contraction, extracellular calcium enters the explained. There is also a potential interaction between
cytosol via the dihydropyridine receptor (DHPR) within the sarcolem- muscular dystrophy and cardiomyopathy, which re-
mal membrane, and induces Ca release via the ryanodine receptor
mains to be clarified. Mouse mdx mutants carry a muta-from the SR. During diastolic relaxation, calcium is taken up into
tion in the dystrophin gene, and exhibit mild muscularthe SR via the SERCA, and is stored in calsequestrin complexes.
dystrophy, but no cardiomyopathy, despite the disap-The amount of calcium taken up via SERCA during diastolic relax-
ation will determine the extent of relaxation and the quantity of pearance of the dystrophin±glycoprotein complex in
calcium available for subsequent quantal release during systole. cardiac and skeletal muscle. Mouse mdx mutants that
Calcium uptake via SERCA is negatively regulated by nonphosphor- also carry a mutation in MyoD, a skeletal muscle specific
ylated phospholamban. Ablation of phospholamban results in in- transcription factor, have a much more severe muscular
creased cardiac contractility and relaxation; while increased inhibi-
dystrophy, due to the inability of the double mutant totion of SERCA by phospholamban has been documented in human
replenish damaged muscle by satellite cell-mediatedheart failure.
regeneration (Megeney et al., 1999). Although MyoD is
skeletal muscle specific, the doubly mutant mice de-
patients often present with associated cardiomyopathy. velop cardiomyopathy. Disruption of the dystrophin±
Mutations in a single sarcoglycan subunit result in re- glycoprotein complex in heart may engender the devel-
duction or absence of the sarcoglycan complex in skele- opment of cardiomyopathy via a secondary response
tal muscle. to a physiological stimulus of volume overload.
Until recently, it has been assumed that the muscle Recent studies of mice lacking a muscle-specific LIM
phenotypes in LGMD patients reflect the intrinsic loss domain protein (MLP) provide further support for an
of the sarcoglycan complex in skeletal or cardiac mus- intrinsic role for cardiomyocyte cytoskeletal proteins in
cle. In the previous issue of Cell, Kevin Campbell and chamber dilation (Arber et al., 1997). MLP is localized
colleagues suggest a novel pathway for the pathogene- in the actin-based cytoskeleton in individual cardiac
sis of cardiomyopathy and muscular dystrophy (Coral- muscle cells (Figure 2). Mice lacking MLP display a se-
Vazquez et al., 1999). The phenotypes of mice lacking vere form of dilated cardiomyopathy with many features
a or d sarcoglycan suggest that disruption of the sarco- of the human disease. MLP contains two LIM domains
glycan subcomplex in vascular smooth muscle is of para- that likely serve as protein±protein interaction modules
that link MLP with other cytoskeletal components. Amount importance. The expression of a and g subunits
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nuclear localization signal is found between the two LIM
domains, and MLP is located in the nucleus. Interest-
ingly, MLP is a transcriptional coactivator for MyoD,
and has previously been reported to be involved in the
myoblast-myotube transition (Kong et al., 1997). Intrigu-
ingly, MLP may regulate cardiac muscle cell transcrip-
tion in a manner similar to that found for cytoskeletal
actin with regards to SRF activation (Sotiropoulos et al.,
1999).
Since over 30% of idiopathic cardiomyopathies are
suspected of having a familial component, utilizing pub-
licly available databases to find sequence variants of
cytoskeletal genes that confer a risk for dilated cardio-
myopathy could also be of value. This approach has
already resulted in the identification of a sequence vari-
ant in the cytoskeletal domain of cardiac actin as a
disease gene in a subset of patients with dilated cardio-
myopathy (Olson et al., 1998). The recent identification Figure 3. Biomechanical Stress Can Induce Myocyte Survival, Cell
Death, and Hypertrophic Pathwaysof a mutation in a nuclear intermediate filament, lamin
Recent in vivo evidence highlights the importance of gp130 andA, in a subset of human dilated cardiomyopathies
neuregulin signaling pathways in modulating cardiac hypertrophy(Bonne et al., 1999), suggests that mutations throughout
or cell death (see text for details).the cytoskeletal network might be linked to chamber
dilation (Figure 2).
Myocyte Survival and Apoptosis Pathways via the constitutive activation of proapoptotic signals
in Dilated Cardiomyopathy (Figure 3).
The loss of functional myocytes can trigger the onset The immediate clinical relevance of myocyte survival
of acute heart failure in cases of myocardial infarction. pathways has been revealed by surprising observations
The loss of cardiac myocytes via cell death pathways in patients receiving ErbB2 receptor antibodies (Hercep-
may also play an important role in the progression of tin) as adjunctive therapy for breast cancer (Slamon et
the chronic course to dilated cardiomyopathy. Apopto- al., 1998). A large-scale clinical trial has documented
sis can occur during cardiac hypertrophy and failure, the efficacy of Herceptin as an adjunctive therapy for
and the increased release of tumor necrosis factor (TNF) metastatic breast cancer, but uncovered the onset of
and other proapoptotic cytokines in the postischemic clinical heart failure in 15% of the patients receiving the
myocardium has been reported. As revealed by cultured drug. The clinical phenotype resembles the rapid onset
myocyte and transgenic animal studies, the overexpres- of dilated cardiomyopathy seen in the gp130 mutant
sion of signaling proteins, such as Gq and p38 MAP
mice. Patients with previous exposure to anthracyclines,
kinases, can trigger a hypertrophic response and lead
are at the highest risk, suggesting a combinatorial effect.
to cardiomyocyte apoptosis (Chien et al., 1999, and ref-
Neuregulin, a secreted peptide found in cardiac endo-
erences therein).
thelium, can directly promote in vitro cardiac myocyte
The recent discovery of myocyte survival pathways
survival via ErbB2±ErbB4 heterodimer pathways (Chienhas provided the strongest evidence to date that the loss
et al., 1999 and references therein), and mutation ofof functional myocytes may drive the onset of chamber
ErbB2 and ErbB4 leads to cardiac myocyte apoptosisdilation in response to biomechanical stress (Hirota et
and an embryonic form of cardiomyopathy (reviewed byal., 1999 and references therein). In 1995, cardiotrophin-1
Marchionni, 1995). Taken together, these results sug-(CT-1), a member of the IL-6 cytokine family, was identi-
gest that neuregulin-dependent pathways may play anfied by expression cloning using an in vitro model of
important role in basal myocyte survival. The recentcardiogenesis in mouse embryonic stem cells. CT-1 is
discovery of gp130±ErbB2 heterodimeric receptors (Qiuone of the most potent cardiac myocyte survival factors
et al., 1998) suggests the fascinating possibility of anthus far described, and acts via gp130/leukemia inhibi-
unknown ligand for cardiac myocyte survival (Figure 3).tory factor receptor b heterodimer pathways to block
Calcium Cycling Defects andmyocyte apoptosis. Mice that harbor a ventricular re-
Dilated Cardiomyopathystricted knockout of gp130 have a normal basal cardiac
The physiological hallmark of all forms of end-stagephenotype, but display rapid onset dilated cardiomyop-
heart failure is the severe loss of cardiac contractileathy and massive myocyte apoptosis following biome-
function. In this regard, decreases in peak calcium tran-chanical stress. Thus, biomechanical stress concomi-
sients have recently been shown to be a feature of end-tantly activates hypertrophic and apoptotic programs,
stage human dilated cardiomyopathy. Since calcium isas evidenced by the shared components in their down-
the currency of cardiac contractility, the potential rolestream signaling pathways. At the same time, the stress-
of calcium regulatory proteins has been of particularactivation of gp130-dependent myocyte survival path-
mechanistic interest. The difficulty has been to distin-ways tilts the balance in favor of hypertrophy, allowing
guish between primary events that drive the progressivethe onset of a compensatory response versus chamber
decline in contractile function versus secondary physio-dilation. The identification of the downstream targets of
logical events.this myocyte survival pathway will allow a rigorous test
The analysis of genetically engineered animals hasof this model, in which hypertrophy per se is viewed as
compensatory, and the transition to heart failure occurs revealed a significant role for sarcoplasmic reticulum
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Chien, K.R., Grace, A.A., and Hunter, J.J. (1999). In The Molecularcalcium cycling as another piece of the dilated cardio-
Basis of Cardiovascular Disease, K.R. Chien, ed. (Philadelphia: W.B.myopathy puzzle. In the normal heart, the action of the
Saunders Company), pp. 211±250.sarcoplasmic reticulum (SR) calcium ATPase pump
Coral-Vazquez, R., Cohn, R.D., Moore, S.A., Hill, J.A., Weiss, R.M.,(SERCA 2) results in the sequestration of calcium in SR,
Davisson, R.L., Straub, V., Barresi, R., Bansal, D., Hrstka, R.F., Wil-
leading to cardiac relaxation (Figure 2). The consequent liamson, R., and Campbell, K.P. (1999). Cell 98, 465±474.
increase in SR calcium stores leads to an increase in Hemler, M.E. (1999). Cell 97, 543±546.
the quantal release of calcium by ryanodine receptors,
Hirota, H., Chen, J., Betz, U.A.K., Rajewsky, K., Gu, Y., Ross, J., Jr.,
the calcium release channels embedded in the SR. In Mueller, W., and Chien, K.R. (1999). Cell 97, 189±198.
this manner, increases in SERCA activity can increase Kadambi, V.J., and Kranias, E.G. (1998). J. Cardiac Failure 4,
both cardiac relaxation and contractility. SERCA 2 activ- 349±361.
ity is regulated by its direct interaction with phospholam- Koch, W.J., Rockman, H.A., Samma, P., Hamilton, R.A., Bond, R.A.,
ban, an endogenous muscle-specific inhibitor of this Milano, C.A., and Lefkowitz, R.J. (1995). Science 268, 1350±1353.
calcium pump (Kadambi and Kranias, 1998, and refer- Kong, Y., Flick, M.J., Kudla, A.J., and Konieczny, S.F. (1997). Mol.
Cell. Biol. 17, 4750±4760.ences therein) that is itself regulated by phosphorylation
via the b-adrenergic receptor/Gs/cAMP pathway (Koch Marchionni, M.A. (1995). Nature 378, 334±335.
et al., 1995, and references therein). cAMP activation of Megeney, L.A., Kablar, B., Perry, R.L., Ying, C., May, L., and Rud-
nicki, M.A. (1999). Proc. Natl. Acad. Sci. USA 96, 220±225.PKA leads to the phosphorylation of phospholamban,
thereby relieving its inhibition of SERCA 2. Intriguingly, Molkentin, J.D., Lu, J.F., Antos, C.L., Markham, B., Richardson, J.,
Robbins, J., Grant, S.R., and Olson, E.N. (1998). Cell 93, 215±228.mice lacking phospholamban display an augmentation
Olson, T.M., Michaels, V.V., Thibodeau, S.N., Tai, Y.S., and Keating,of both cardiac contractility and relaxation, without any
M.T. (1998). Science 280, 750±752.long-term pathological effects (Kadambi and Kranias,
Qiu, Y., Ravi, L., and Kung, H.J. (1998). Nature 393, 83±85.1998). In addition, overexpression of a peptide inhibitor
Rockman, H.A., Chien, K.R., Choi, D.-J., Iaccarino, G., Hunter, J.J.,of the b-adrenergic receptor kinase (Koch et al., 1995)
Ross, J., Jr., Lefkowitz, R.J., and Koch, W.J. (1998). Proc. Natl. Acad.can rescue the heart failure phenotype of MLP-deficient
Sci. USA 95, 7000±7005.mice with dilated cardiomyopathy (Rockman et al.,
Seidman, C.E., and Seidman, J.G. (1999). In The Molecular Basis of1998). Since phospholamban is regulated by the b-adren-
Cardiovascular Disease, K.R. Chien, ed. (Philadelphia: W.B. Saun-
ergic pathway, SR calcium cycling defects provide a ders Company), pp. 251±263.
potential molecular mechanism for the progressive de- Slamon, D., Leyland-Jones, B., Shak, S., Paton, V., Bajamonde, A.,
crease in cardiac contractility and relaxation in dilated Fleming, T., Eiermann, W., Wolter, J., Baselga, J., and Norton, L.
cardiomyopathy. A calcineurin-dependent pathway can (1998). Proc. Am. Soc. Clin. Oncol. 17, 98a.
regulate the fetal gene program during hypertrophy Sotiropoulos, A., Gineitis, D., Copeland, J., and Treisman, R. (1999).
Cell 98, 159±169.(Molkentin et al., 1998), supporting a direct role of cal-
cium as a signal for specific phenotypic features of di-
lated cardiomyopathy. Accordingly, establishing ge-
netic-based screens for known and novel coregulators
of SR calcium content in heart muscle cells could be of
value.
Summary
Stress-related pathways can be linked to each of these
four pieces of the dilated cardiomyopathy puzzle: bio-
mechanical stimuli, cytoskeletal signaling, myocyte sur-
vival, and SR calcium cycling. While the ªcholesterolº of
dilated cardiomyopathy has yet to be identified, genetic
clustering suggests the likelihood that chronic increases
in wall stress mediated via cytoskeletal pathways may
lead to the concomitant activation of downstream ef-
fects on myocyte survival, apoptosis, hypertrophy, and
calcium cycling that drive the progression of heart fail-
ure. If such is the case, it may become possible to re-
verse the process of dilated cardiomyopathy by relieving
wall stress at the molecular level. Given the pace and
quality of recent work from many laboratories, the solu-
tion to the puzzle of heart failure may be closer than
previously imagined.
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